AssetMark Inc’s Rhythm Pharmaceuticals RYTM Stock Holding History

AssetMark Inc’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$286	Buy	+3	New	+$320	﹤0.01%	3551

Other funds holding RYTM

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Capricorn Fund Managers London, United Kingdom $1.06B AUM 45.98% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

iA Global Asset Management Quebec, Quebec, Canada $8.54B AUM 39.73% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

AssetMark Inc's RYTM Position: Q3 2026 in Review

AssetMark Inc opened a new position in Rhythm Pharmaceuticals (RYTM) in Q3 2026: 3 shares worth $286. The stake represents ﹤0.01% of the portfolio and ranks #3551 among its holdings.

83 funds tracked by Wall St. Rank hold RYTM as of Q3 2026.

AssetMark Inc held 3 shares of Rhythm Pharmaceuticals worth $286 as of Q3 2026.
Rhythm Pharmaceuticals was a new AssetMark Inc position in Q3 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #3551 holding.
83 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.